Skip to main content
Transgene logo

Transgene — Investor Relations & Filings

Ticker · TNG ISIN · FR0005175080 LEI · 969500PDJW8N0FSGGK69 PA Professional, scientific and technical activities
Open in API
Filings indexed 796 across all filing types
Latest filing 2021-04-01 Report Publication Anno…
Country FR France
Listing PA TNG

About Transgene

https://www.transgene.fr/en/

Transgene is a clinical-stage biotechnology company that designs and develops immunotherapies for the treatment of cancer. The company's strategy is based on two proprietary technology platforms. The myvac® platform is used to create individualized neoantigen therapeutic vaccines, such as its clinical candidate TG4050, which leverages advanced genetic engineering and artificial intelligence. The invir.IO® platform is dedicated to developing innovative, multifunctional oncolytic viruses engineered to directly destroy cancer cells and modulate the tumor microenvironment, thereby enhancing the patient's immune response against the tumor.

Recent filings

Filing Released Lang Actions
Modalités de mise à disposition de document de référence ou de ses actualisations
Report Publication Announcement Classification · 1% confidence The document is a short press release (1237 characters) dated April 1, 2021, announcing that Transgene has made its 'document d'enregistrement universel 2020' (Universal Registration Document 2020) available to the public and filed it with the AMF (Autorité des marchés financiers). The text explicitly states the document is 'mis à la disposition du public' (made available to the public) and lists the components included within it (annual financial report, governance report, auditor reports, etc.). According to Rule #2 (The 'MENU VS MEAL' Rule), when a document announces the publication or availability of a larger report rather than containing the full report itself, it should be classified as a Report Publication Announcement (RPA).
2021-04-01 French
Document d'enregistrement universel 2020
Annual Report Classification · 1% confidence The document is a 'Document d'Enregistrement Universel' (Universal Registration Document) for the fiscal year 2020, filed by Transgene. In the context of European financial reporting, this document serves as the comprehensive annual report, containing audited financial statements, management reports, risk factors, and governance information. While it is a regulatory filing, it functions as the primary annual report for the company, which aligns with the 10-K category in the provided schema. FY 2020
2021-03-31 French
Informations privilégiées / Autres communiqués
Legal Proceedings Report Classification · 1% confidence The document is a press release dated March 10, 2021, from Transgene announcing the launch of a new Phase II randomized controlled trial comparing TG4001 in combination with avelumab versus avelumab alone for HPV16-positive anogenital cancers. It details the trial objectives, patient population, endpoints (PFS, ORR, OS), collaboration with Merck KGaA and Pfizer, and provides an expected timeline for interim data communication (end of 2022). It also references prior data presented at SITC 2020 and ESMO IO 2020. This content is characteristic of an announcement regarding clinical trial progress and results, which falls under the scope of general investor/corporate news. Since it is a detailed announcement about clinical development and not a formal regulatory filing (like 10-K or AR), nor a transcript (CT), nor a formal presentation (IP), the most appropriate classification is 'Regulatory Filings' (RNS) as a general corporate/clinical update, or potentially 'Investor Presentation' (IP) if it were structured as slides, but given the press release format detailing trial updates, RNS is the best fit among the available options for non-standard, ongoing corporate news.
2021-03-10 French
Inside Information / Other news releases
Investor Presentation Classification · 1% confidence The document is a press release from Transgene dated March 10, 2021, announcing the expansion of a Phase II clinical trial for their therapeutic vaccine TG4001 in combination with avelumab. It details trial design, endpoints (PFS, ORR, OS), collaboration with Merck KGaA/Pfizer, expected timelines for interim analysis (end of 2022), and references prior data presentations (SITC 2020, ESMO IO 2020). This content structure—a formal announcement detailing clinical trial progress, collaboration updates, and future milestones—is characteristic of an Investor Presentation (IP) or a detailed corporate update, rather than a brief Earnings Release (ER) or a comprehensive Annual Report (10-K). Since it is a detailed presentation of strategy and clinical data aimed at investors, Investor Presentation (IP) is the most appropriate classification. It is not a simple announcement of a report (RPA/RNS) because it contains substantial, original content about the trial expansion and data interpretation.
2021-03-10 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated March 2, 2021, announcing that Transgene's teams will be presenting scientific expertise at several upcoming scientific conferences (ESMO, Royal Society, European Neoantigen Summit) in March and April 2021. It details the specific presentations and speakers. This content is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement related to investor/scientific communication regarding future events and company pipeline updates. Since it is an announcement about scientific participation and pipeline progress, it fits best under Investor Presentation (IP) if it were the presentation itself, but as an announcement *about* presentations at external scientific meetings, it is a general corporate communication. Given the options, it is a specific type of corporate update that doesn't fit the primary financial reports. However, since it details scientific progress and future presentations, it is closely related to investor relations material. It is not a proxy statement (PSI), management discussion (MDA), or a formal report (AR, 10-K, IR). It is most closely aligned with general investor communication, but none of the codes perfectly capture 'Scientific Conference Update'. Given the choices, and recognizing that detailed pipeline updates are often bundled with Investor Presentations (IP) or treated as general Regulatory Filings (RNS) if no better fit exists, I will evaluate the nature. This is a proactive communication about scientific milestones and visibility. It is not a formal report itself, nor a dividend notice, nor a management change. It is a specific update on scientific engagement. Since it is a press release detailing future scientific engagement, and not a formal financial report, the closest fit among the specific categories is difficult. However, it is a form of communication intended for investors and the scientific community. If we must choose from the list, and recognizing it is not a formal financial report, it defaults to a general announcement. But since it details specific scientific data presentation plans, it is more specific than RNS. It is not a proxy (PSI) or remuneration report (DEF 14A). It is a general corporate update. I will classify it as a Regulatory Filing (RNS) as a catch-all for specific, non-standard corporate announcements, although it shares characteristics with Investor Presentation material.
2021-03-02 French
Inside Information / Other news releases
Report Publication Announcement Classification · 1% confidence The document is a press release announcing that Transgene management and scientific staff will be presenting data at several upcoming scientific conferences (ESMO, Royal Society Meeting, European Neoantigen Summit). It details the topics, speakers, and dates of these presentations. This type of announcement, which informs investors and the public about participation in scientific/investor events, most closely aligns with an Investor Presentation (IP) or a general announcement. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a formal regulatory filing about a specific transaction (like DIRS or DIV), and it focuses on scientific updates intended for an investor audience, 'Investor Presentation (IP)' is the most appropriate fit, as these announcements often precede or accompany investor-focused materials. However, given the structure is a press release announcing *future* participation, it functions as a general corporate update. Since 'IP' covers detailed presentations, and this document is an announcement *about* presentations, it could also be considered a Regulatory Filing (RNS) if no better fit exists. Comparing the options, the content is highly focused on scientific milestones and future presentations, which is a key component of investor relations material. I will classify it as Investor Presentation (IP) because the core subject is the scientific/clinical data being shared at investor-relevant forums, even though it's delivered via a press release format.
2021-03-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.